No Data
Yao Kang Biologics (688046.SH): Plans to promote the employee stock ownership plan for 2025.
On March 24, Glonghui reported that Yao Kang Biotechnology (688046.SH) announced its employee stock ownership plan for 2025. The stocks for this employee stock ownership plan are sourced from the common shares of Biotechnology A repurchased by the company's repurchase account. The plan intends to hold approximately 2.04 million stocks, accounting for about 0.50% of the company's total capital of 410 million stocks at the time the draft of this employee stock ownership plan was announced, with the specific number of stocks depending on the buyback situation. After the draft of this employee stock ownership plan is approved by the company’s shareholders' meeting, it will obtain the company's repurchased special securities account through non-trading transfers and other methods permitted by laws and regulations.
GemPharmatech (SHSE:688046) Has A Pretty Healthy Balance Sheet
YaoKang Biotech (688046.SH): A total of 0.2169% of the company's shares have been repurchased.
On March 4, Gelonghui reported that Yaokang Biological (688046.SH) announced that as of February 28, 2025, the company has cumulatively repurchased 889,185 shares of the company through the concentrated bidding trading method via the Shanghai Stock Exchange trading system, accounting for 0.2169% of the company's total share capital of 410,000,000 shares. The highest transaction price was 15.13 yuan/share, and the lowest price was 12.17 yuan/share, with a total payment of 11,946,559.53 yuan (excluding stamp tax, transaction commission, and other trading fees).
Yakkang Biotech: Yakang Biotech 2024 Annual Performance Report Announcement
Yakkang Biotech 2024 Annual Results Express Announcement
YaoKang Bio (688046.SH): Net income for the year 2024 is 0.116 billion yuan, a decrease of 27.14% year-on-year.
On February 27, Gelonghui reported that Yaokang Biotechnology (688046.SH) announced its performance forecast for the year 2024. During the reporting period, the company achieved revenue of 686.7998 million yuan, an increase of 10.38% compared to the same period last year; it achieved a net income attributable to the parent company of 115.7887 million yuan, a decrease of 27.14% compared to the same period last year; it achieved a net income attributable to the parent company, deducting non-recurring gains and losses, of 81.9228 million yuan, a decrease of 23.57% compared to the same period last year.
Investor Optimism Abounds GemPharmatech Co., Ltd. (SHSE:688046) But Growth Is Lacking